Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Effects of Anesthesia on Maternal and Fetal Oxidative Stress During Cesarean Delivery

5 november 2026 bijgewerkt door: University of Banja Luka

The Impact of Target-Controlled Infusion of Propofol on Fetal Oxidative Stress During Anesthesia for Cesarean Section

Oxidative stress occurs when the production of reactive molecules exceeds the body's antioxidant defenses. Pregnancy is associated with physiological changes that may increase oxidative stress in both the mother and fetus. The type of anesthesia used during cesarean delivery may influence this process.

This study aimed to investigate whether general anesthesia using target-controlled infusion (TCI) of propofol affects maternal and fetal oxidative stress compared with spinal anesthesia and general anesthesia using thiopental and sevoflurane.

A total of 90 healthy pregnant women undergoing elective cesarean delivery were included in this prospective study. Participants were divided into three groups of 30: spinal anesthesia, propofol-based general anesthesia, and thiopental-sevoflurane general anesthesia.

Maternal venous blood, umbilical venous blood, and placental tissue samples were collected to assess biochemical markers of oxidative stress and antioxidant defense. Clinical and anesthesia-related data were also recorded.

The study was designed to compare oxidative stress markers across the three anesthesia techniques and evaluate the potential antioxidant effects of propofol on the mother and fetus.

Studie Overzicht

Gedetailleerde beschrijving

This prospective, open-label clinical study was conducted at the University Clinical Centre of the Republic of Srpska in Banja Luka, Bosnia and Herzegovina, to investigate the effects of different anesthetic techniques on maternal and fetal oxidative stress during elective cesarean delivery.

The study included 90 pregnant women with uncomplicated pregnancies undergoing elective cesarean delivery. Participants were allocated to three groups of 30 according to the anesthetic technique: spinal anesthesia (Group S), general anesthesia with target-controlled infusion of propofol (Group P), and general anesthesia with thiopental induction followed by sevoflurane maintenance (Group TS).

Maternal venous blood, umbilical venous blood, and placental tissue samples were collected to assess oxidative stress and antioxidant defense mechanisms. The biochemical analyses included markers of lipid peroxidation, reactive oxygen species, and antioxidant activity, including thiobarbituric acid-reactive substances (TBARS), nitrites, hydrogen peroxide, superoxide anion, superoxide dismutase (SOD), reduced glutathione (GSH), and catalase (CAT).

Maternal hemodynamic parameters, anesthetic drug administration, neonatal clinical outcomes, and postoperative maternal outcomes were also evaluated.

The study aimed to compare oxidative stress responses across the three anesthetic techniques and investigate whether propofol-based total intravenous anesthesia provides potential antioxidant benefits in the maternal-placental-fetal system.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

90

Fase

  • Fase 4

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Republika Srpska
      • Banja Luka, Republika Srpska, Bosnië-Herzegovina, 78000
        • University Clinical Centre of the Republic of Srpska

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

  • Uncomplicated singleton pregnancy.
  • Estimated fetal weight greater than 2500 g.
  • Scheduled elective cesarean delivery.
  • Written informed consent to participate in the study.

Exclusion Criteria:

  • Emergency cesarean delivery.
  • Thrombophilia.
  • Hypertensive disorders of pregnancy.
  • Diabetes mellitus.
  • Maternal smoking.
  • Intrauterine fetal growth restriction (IUGR).
  • Fetal malformations.
  • Intrauterine fetal death.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Fundamentele wetenschap
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Arm 1 - Spinal anesthesia

Thirty women undergoing elective cesarean section under spinal anesthesia.

Spinal anesthesia administered for elective cesarean section as part of routine clinical care.

Experimenteel: Arm 2 - Propofol TCI

Thirty women undergoing elective cesarean section under general anesthesia using target-controlled infusion of propofol.

General anesthesia using target-controlled infusion of propofol for elective cesarean section.

Actieve vergelijker: Arm 3 - Thiopental-Sevoflurane

Thirty women undergoing elective cesarean section under general anesthesia with thiopental induction and sevoflurane maintenance.

Thiopental was administered intravenously for induction of general anesthesia in women undergoing elective cesarean section. Anesthesia was subsequently maintained with sevoflurane.

Sevoflurane was administered by inhalation for maintenance of general anesthesia during elective cesarean section, following intravenous induction with thiopental.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Maternal Plasma TBARS Concentration
Tijdsspanne: Before anesthesia, during cesarean delivery, and 2 hours postoperatively.

Thiobarbituric acid-reactive substances (TBARS), an indicator of lipid peroxidation, measured in maternal plasma. Concentrations were compared across the three anesthesia groups and assessed at three perioperative time points. Values are expressed in mmol/L.

Before anesthesia, during cesarean delivery, and 2 hours postoperatively.
Umbilical Cord Venous Plasma TBARS Concentration
Tijdsspanne: At delivery (umbilical cord venous blood sampling).

Thiobarbituric acid-reactive substances (TBARS), an indicator of lipid peroxidation, measured in umbilical cord venous plasma. Concentrations were compared across the three anesthesia groups. Values are expressed in mmol/L.

At delivery (umbilical cord venous blood sampling).
Placental Tissue TBARS Concentration
Tijdsspanne: At delivery, immediately following placental removal.

Thiobarbituric acid-reactive substances (TBARS), an indicator of lipid peroxidation, measured in placental tissue homogenates. Concentrations were compared across the three anesthesia groups. Values are expressed in µmol/g of tissue.

At delivery, immediately following placental removal.
Maternal Plasma Hydrogen Peroxide (H2O2) Concentration
Tijdsspanne: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Hydrogen peroxide (H2O2), a marker of oxidative stress, measured in maternal plasma. Concentrations were compared across the three anesthesia groups at three perioperative time points. Values are expressed in nmol/mL.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Plasma Hydrogen Peroxide (H2O2) Concentration
Tijdsspanne: At delivery (umbilical cord venous blood sampling).

Hydrogen peroxide (H2O2), a marker of oxidative stress, measured in umbilical cord venous plasma. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/mL.

At delivery (umbilical cord venous blood sampling).
Maternal Plasma Superoxide Anion (O2-) Concentration
Tijdsspanne: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Superoxide anion (O2-), a reactive oxygen species and marker of oxidative stress, measured in maternal plasma. Concentrations were compared across the three anesthesia groups at three perioperative time points. Values are expressed in nmol/mL.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Plasma Superoxide Anion (O2-) Concentration
Tijdsspanne: At delivery (umbilical cord venous blood sampling).

Superoxide anion (O2-), a reactive oxygen species and marker of oxidative stress, measured in umbilical cord venous plasma. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/mL.

At delivery (umbilical cord venous blood sampling).
Maternal Plasma Nitrite (NO2-) Concentration
Tijdsspanne: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Nitrite (NO2-), an indicator of nitric oxide metabolism, measured in maternal plasma. Concentrations were compared across the three anesthesia groups at three perioperative time points. Values are expressed in nmol/mL.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Plasma Nitrite (NO2-) Concentration
Tijdsspanne: At delivery (umbilical cord venous blood sampling).

Nitrite (NO2-), an indicator of nitric oxide metabolism, measured in umbilical cord venous plasma. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/mL.

At delivery (umbilical cord venous blood sampling).
Maternal Erythrocyte Superoxide Dismutase (SOD) Activity
Tijdsspanne: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Superoxide dismutase (SOD) activity, an indicator of enzymatic antioxidant defense, measured in maternal erythrocyte lysates. Activity was compared across the three anesthesia groups at three perioperative time points. Values are expressed in U/g Hgb × 10³.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Erythrocyte Superoxide Dismutase (SOD) Activity
Tijdsspanne: At delivery (umbilical cord venous blood sampling).

Superoxide dismutase (SOD) activity, an indicator of enzymatic antioxidant defense, measured in erythrocyte lysates from umbilical cord venous blood. Activity was compared across the three anesthesia groups. Values are expressed in U/g Hgb × 10³.

At delivery (umbilical cord venous blood sampling).
Placental Tissue Superoxide Dismutase (SOD) Activity
Tijdsspanne: At delivery, following placental removal.

Superoxide dismutase (SOD) activity, an indicator of enzymatic antioxidant defense, measured in placental tissue homogenates. Activity was compared across the three anesthesia groups. Values are expressed in U/g of tissue.

At delivery, following placental removal.
Maternal Erythrocyte Reduced Glutathione (GSH) Concentration
Tijdsspanne: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Reduced glutathione (GSH), a non-enzymatic antioxidant involved in cellular defense against oxidative stress, measured in maternal erythrocyte lysates. Concentrations were compared across the three anesthesia groups at three perioperative time points. Values are expressed in nmol/mL RBC.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Erythrocyte Reduced Glutathione (GSH) Concentration
Tijdsspanne: At delivery (umbilical cord venous blood sampling).

Reduced glutathione (GSH), a non-enzymatic antioxidant involved in cellular defense against oxidative stress, measured in erythrocyte lysates from umbilical cord venous blood. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/mL RBC.

At delivery (umbilical cord venous blood sampling).
Placental Tissue Reduced Glutathione (GSH) Concentration
Tijdsspanne: At delivery, following placental removal.

Reduced glutathione (GSH), a non-enzymatic antioxidant involved in cellular defense against oxidative stress, measured in placental tissue homogenates. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/g of tissue.

At delivery, following placental removal.
Maternal Erythrocyte Catalase (CAT) Activity
Tijdsspanne: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Catalase (CAT) activity, an indicator of enzymatic antioxidant defense, measured in maternal erythrocyte lysates. Activity was compared across the three anesthesia groups at three perioperative time points. Values are expressed in U/g Hgb × 10³.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Erythrocyte Catalase (CAT) Activity
Tijdsspanne: At delivery (umbilical cord venous blood sampling).

Catalase (CAT) activity, an indicator of enzymatic antioxidant defense, measured in erythrocyte lysates from umbilical cord venous blood. Activity was compared across the three anesthesia groups. Values are expressed in U/g Hgb × 10³.

At delivery (umbilical cord venous blood sampling).
Placental Tissue Catalase (CAT) Activity
Tijdsspanne: At delivery, following placental removal.

Catalase (CAT) activity, an indicator of enzymatic antioxidant defense, measured in placental tissue homogenates. Activity was compared across the three anesthesia groups. Values are expressed in U/g of tissue.

At delivery, following placental removal.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Umbilical Cord Blood pH
Tijdsspanne: At delivery (umbilical cord blood sampling).

Umbilical cord blood pH measured by blood gas analysis immediately after delivery to assess neonatal acid-base status. Values were compared across the three anesthesia groups. pH is dimensionless.

At delivery (umbilical cord blood sampling).
Umbilical Cord Blood Partial Pressure of Oxygen (pO₂)
Tijdsspanne: At delivery (umbilical cord blood sampling).

Partial pressure of oxygen (pO₂) measured in umbilical cord blood by blood gas analysis to assess neonatal oxygenation at birth. Values were compared across the three anesthesia groups. Results are expressed in mmHg.

At delivery (umbilical cord blood sampling).
Umbilical Cord Blood Partial Pressure of Carbon Dioxide (pCO₂)
Tijdsspanne: At delivery (umbilical cord blood sampling).

Partial pressure of carbon dioxide (pCO₂) measured in umbilical cord blood by blood gas analysis to assess neonatal acid-base status at birth. Values were compared across the three anesthesia groups. Results are expressed in mmHg.

At delivery (umbilical cord blood sampling).
Umbilical Cord Blood Base Excess (BE)
Tijdsspanne: At delivery (umbilical cord blood sampling).

Base excess (BE) measured in umbilical cord blood by blood gas analysis to assess neonatal metabolic acid-base status at birth. Values were compared across the three anesthesia groups. Results are expressed in mmol/L.

At delivery (umbilical cord blood sampling).
Umbilical Cord Blood Lactate Concentration
Tijdsspanne: At delivery (umbilical cord blood sampling).

Lactate concentration measured in umbilical cord blood by blood gas analysis to assess neonatal metabolic status at birth. Values were compared across the three anesthesia groups. Results are expressed in mmol/L.

At delivery (umbilical cord blood sampling).
Maternal Venous Blood pH
Tijdsspanne: Intraoperatively, during cesarean delivery.

Maternal venous blood pH measured by blood gas analysis during cesarean delivery to assess maternal acid-base status. Values were compared across the three anesthesia groups. pH is dimensionless.

Intraoperatively, during cesarean delivery.
Maternal Venous Blood Partial Pressure of Oxygen (pO₂)
Tijdsspanne: Intraoperatively, during cesarean delivery.

Partial pressure of oxygen (pO₂) measured in maternal venous blood by blood gas analysis during cesarean delivery to assess maternal venous oxygenation. Values were compared across the three anesthesia groups. Results are expressed in mmHg.

Intraoperatively, during cesarean delivery.
Maternal Venous Blood Partial Pressure of Carbon Dioxide (pCO₂)
Tijdsspanne: Intraoperatively, during cesarean delivery.

Partial pressure of carbon dioxide (pCO₂) measured in maternal venous blood by blood gas analysis during cesarean delivery to assess maternal acid-base and respiratory status. Values were compared across the three anesthesia groups. Results are expressed in mmHg.

Intraoperatively, during cesarean delivery.
Intraoperatively, during cesarean delivery.
Tijdsspanne: Intraoperatively, during cesarean delivery.

Lactate concentration measured in maternal venous blood by blood gas analysis during cesarean delivery to assess maternal metabolic status. Values were compared across the three anesthesia groups. Results are expressed in mmol/L.

Intraoperatively, during cesarean delivery.
Maternal Venous Blood Base Excess (BE)
Tijdsspanne: Intraoperatively, during cesarean delivery.

Base excess (BE) measured in maternal venous blood by blood gas analysis during cesarean delivery to assess maternal metabolic acid-base status. Values were compared across the three anesthesia groups. Results are expressed in mmol/L.

Intraoperatively, during cesarean delivery.
Maternal White Blood Cell Count (WBC)
Tijdsspanne: Intraoperatively and 2 hours after delivery.

Maternal white blood cell (WBC) count measured in venous blood as part of a complete blood count to assess maternal hematological status. Values were compared across the three anesthesia groups. Results are expressed in ×10⁹/L.

Intraoperatively and 2 hours after delivery.
Maternal C-Reactive Protein (CRP) Concentration
Tijdsspanne: Intraoperatively and 2 hours after delivery.

Maternal C-reactive protein (CRP) concentration measured in venous blood to assess maternal inflammatory status. Values were compared across the three anesthesia groups. Results are expressed in mg/L.

Intraoperatively and 2 hours after delivery.
Intraoperatively and 2 hours after delivery.
Tijdsspanne: 48-72 hours after birth.

Neonatal white blood cell (WBC) count measured in venous blood as part of a complete blood count to assess neonatal hematological status. Values were compared across the three maternal anesthesia groups. Results are expressed in ×10⁹/L.

48-72 hours after birth.
Neonatal C-Reactive Protein (CRP) Concentration
Tijdsspanne: 48-72 hours after birth.

Neonatal C-reactive protein (CRP) concentration measured in venous blood to assess neonatal inflammatory status. Values were compared across the three maternal anesthesia groups. Results are expressed in mg/L.

48-72 hours after birth.
Maternal Mean Arterial Pressure (MAP)
Tijdsspanne: Before anesthesia (minute 0) and at 2, 4, 6, 8, and 10 minutes after anesthesia initiation, until delivery.

Maternal mean arterial pressure (MAP) was calculated from noninvasively measured systolic and diastolic arterial blood pressure values. Measurements were obtained before anesthesia and at 2-minute intervals after anesthesia initiation. MAP values were compared across the three anesthesia groups and expressed in mmHg.

Before anesthesia (minute 0) and at 2, 4, 6, 8, and 10 minutes after anesthesia initiation, until delivery.
Maternal Heart Rate (HR)
Tijdsspanne: Before anesthesia (minute 0) and at 2, 4, 6, 8, and 10 minutes after anesthesia initiation.

Maternal heart rate (HR) measured by standard intraoperative monitoring before anesthesia and at 2-minute intervals after anesthesia initiation. Measurements were compared across the three anesthesia groups. Results are expressed in beats per minute (bpm).

Before anesthesia (minute 0) and at 2, 4, 6, 8, and 10 minutes after anesthesia initiation.
Patient-Reported Anesthesia-Related Adverse Effects
Tijdsspanne: On the first postoperative day (24 hours after anesthesia).

Anesthesia-related adverse effects were assessed using the Bauer questionnaire on the first postoperative day. Ten symptoms were evaluated: postoperative pain, drowsiness, thirst, hoarseness, sore throat, nausea and vomiting, feeling cold, difficulty concentrating, pain at the anesthetic administration site, and shivering. The outcome was expressed as the number and percentage of patients reporting each adverse effect, separately for each anesthesia group.

On the first postoperative day (24 hours after anesthesia).
Intraoperative Awareness During General Anesthesia
Tijdsspanne: On the first postoperative day (24 hours after anesthesia).

Intraoperative awareness was assessed in patients receiving general anesthesia using the modified Brice questionnaire. Patients were asked about their last memory before anesthesia, first memory after awakening, any recollection of events during surgery, and dreams during anesthesia. The occurrence of reported intraoperative awareness was compared between the propofol TCI and thiopental-sevoflurane groups. The outcome was expressed as the number and percentage of patients reporting intraoperative awareness.

On the first postoperative day (24 hours after anesthesia).
Neonatal Apgar Score at 1 Minute
Tijdsspanne: 1 minute after birth.

Neonatal condition was assessed using the Apgar score at 1 minute after birth. The score evaluates five components: heart rate, respiratory effort, muscle tone, reflex irritability, and skin color. Each component is scored from 0 to 2, resulting in a total score ranging from 0 to 10. Apgar scores were compared across the three maternal anesthesia groups. Higher Apgar scores indicate better neonatal clinical condition.

1 minute after birth.
Neonatal Apgar Score at 5 Minutes
Tijdsspanne: 5 minutes after birth.

Neonatal condition was assessed using the Apgar score at 5 minutes after birth. The score evaluates five components: heart rate, respiratory effort, muscle tone, reflex irritability, and skin color. Each component is scored from 0 to 2, resulting in a total score ranging from 0 to 10. Apgar scores were compared across the three maternal anesthesia groups. Higher Apgar scores indicate better neonatal clinical condition.

5 minutes after birth.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 november 2022

Primaire voltooiing (Werkelijk)

19 februari 2024

Studie voltooiing (Werkelijk)

19 februari 2024

Studieregistratiedata

Eerst ingediend

31 oktober 2026

Eerst ingediend dat voldeed aan de QC-criteria

5 november 2026

Eerst geplaatst (Werkelijk)

12 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

12 november 2026

Laatste update ingediend die voldeed aan QC-criteria

5 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Individual participant data will not be shared because data sharing was not included in the original study protocol or informed consent procedures.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren